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ABSTRACT
Prophylactic cancer vaccination presents novel opportunities to improve the health and wellbeing of populations. Since the approval of a cervical cancer vaccine against human
papillomavirus (HPV) in 2006, only three states have passed legislation adding it to their schoolentry schedules of required vaccinations. Despite ample evidence of its safety and efficacy, the
vaccine remains controversial, and national vaccination rates among both girls and boys remain
low. Risk for HPV-related cancers varies by population, and Appalachian Kentucky has among
the highest HPV-related morbidity and mortality in the nation. Annual attempts to pass HPV
vaccine legislation in Kentucky have so far failed in the absence of directly targeted quantitative
data on the risks and rewards of action vs. inaction. We herein present the first known impact
assessment of an HPV vaccine school entry requirement for the state of Kentucky, using a
transmission-dynamic model to simulate vaccine scenarios in the context of Kentucky’s high
HPV disease burden and unique population characteristics. Our findings suggest that over the
lifetime of those first vaccinated after passage, such a policy could prevent approximately 18
thousand cancers and 3 thousand deaths; preserve 18 thousand life-years and more than 34
thousand quality-adjusted life years; and save as much as 1.3 billion USD in the state of
Kentucky.
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ACRONYMS AND ABBREVIATIONS
13RS-HB358 – 2013 Regular Session, House Bill 358
4vHPV – Quadrivalent HPV
9vHPV – Nonavalent HPV
AAFP – American Academy of Family Physicians
AAP – American Academy of Pediatrics
ACIP – Advisory Committee on Immunization Practices
ACOG – American College of Obstetricians and Gynecologists
ACP – American College of Physicians
ASTHO – Association of State and Territorial Health Officials
CAST – Centre for Applied Health Services Research and Technology
CDC – Centers for Disease Control and Prevention
CPSTF – Community Preventive Services Task Force
DCC – Distant Metastatic Cervical Cancer
FDA – Food and Drug Administration
HHS – Department of Health and Human Services
HPV – Human Papillomavirus
HPV-MOK – Human Papillomavirus Model of Kentucky
ICER – Incremental Cost-Effectiveness Ratio
JORRP – Juvenile Onset Recurrent Respiratory Papillomatosis
LCC – Locally Invasive Cervical Cancer
NGO – Non-governmental Organization
OECD – Organization for Economic Co-operation and Development
Pap – Papanicolaou
PCE – Personal Consumption Expenditure
PV – Present Value
QALY – Quality Adjusted Life Year
RCC – Regionally Invasive Cervical Cancer
SIS – Susceptible-Infectious-Susceptible
TDAP – Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine
USA – United States of America
USD – United States Dollar
WHO – World Health Organization
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INTRODUCTION
The possibility of cancer prevention by vaccination has tantalized physicians, scientists,
and the public health community for over a century, at least since Coley’s attempts to use
bacterial immunotherapy for cancer treatment laid the foundation for the use of Bacillus
Calmette-Guérin to prevent the recurrence of superficial bladder cancer.1 Later, vaccination
against Hepatitis B to prevent hepatocellular carcinoma was based on Blumberg’s Nobel Prizewinning work demonstrating the causal link between hepatitis B and HCC during the 1960s and
’70s.1
But these developments were only harbingers of the idea’s potential, recurrent bladder
and hepatitis B-related liver cancers being relatively rare. The biggest breakthrough in cancer
vaccination to date emerged during the early 1990s from clinical trials testing the safety and
efficacy of vaccines against two human papillomavirus (HPV) types implicated in cervical
cancer1 - the second most common cancer among women in highly developed countries, and a
leading female malignancy and cause of death among middle-aged women in ‘developing’
nations.2 The Food and Drug Administration (FDA) subsequently approved a quadrivalent HPV
(4vHPV) vaccine (Gardasil™, Merck & Co., Inc.)3 covering types 6, 11, 16, and 18 for the
prevention of genital warts and cervical cancers in 2006,1 making it the first licensed vaccine
against a common sexually transmitted infection.4 Together, these four HPV types etiologically
account for approximately 68% of squamous cell cervical cancers, 83% of adenocarcinomas of
the cervix, 90% of anogenital condylomas,5 and a large fraction of all other anogenital and
oropharyngeal dysplasias and malignancies in both males and females.5,6 A nonavalent (9vHPV)
vaccine was approved by the FDA in 2015, which adds the high-risk types 31, 33, 45, 52, and 58,
and has the potential to prevent the large majority of all health-relevant HPV infections.7
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Though the vast majority of countries set vaccine policy at the national level, the United
States (USA) does not. Instead, each state, district, or territory retains authority to set public
health policy, including vaccine policy. Nevertheless, the USA has a long history of mandatory
vaccination, with conditions for school entry dating back to the early 1800s.8 Today, all 50 of her
states have school-entry vaccine laws, but only three states or districts – Washington, D.C.,
Virginia, and Rhode Island – have so far added the HPV vaccine to their respective school entry
schedules, despite strong endorsement of school entry policies to increase vaccine schedule
adherence from the Community Preventive Services Task Force (CPSTF),9 the Association of
State and Territorial Health Officials (ASTHO),10 and public health agencies throughout the
USA. The Centers for Disease Control and Prevention (CDC) HPV vaccine recommendations
are for both females and males, but so far only Rhode Island’s legislation has included males in
its mandate.11
The reasons for failure of state lawmakers to move HPV vaccine legislation forward are
complex. Here, it is sufficient to note that this failure is not due to a lack of evidence for, or
informed support of, the effectiveness of school entry requirements to increase vaccine uptake,
population coverage, and disease reduction. According to the CPSTF’s systematic review of
seventeen scientific studies examining the effectiveness of state or local vaccination
requirements on changes in vaccination rates, the median change was an increase of 18%.12
Other studies reviewed in their report found significant reductions in vaccine-preventable disease
rates in states with school entry laws requiring that vaccine.9,12
Kentucky was among the first states to propose HPV vaccine legislation immediately
following the FDA’s approval and the CDC’s recommendation release in 2006. But here, as
elsewhere in the country, the legislation faced a large pushback that continues today. Kentucky-
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specific quantitative data is one critical factor missing from the HPV vaccine policy discussion in
Kentucky’s capital, Frankfort. Until recently, the epidemiology of HPV in Kentucky was
presumed to match that estimated for the USA’s general population. But data published in 2017
identified prevalence rates in Appalachian Kentucky 2-5 times higher than national age-matched
averages,13 consistent with the high incidence of HPV-related cancers at-large in Kentucky, and
the even higher rates observed in the Appalachian region of the state.
New information creates new possibilities. New targeted prevalence data can now be
used to inform population-specific modeling of the potential impact of legislation adding the
HPV vaccine to the school entry schedule in Kentucky. This paper presents one such quantitative
estimate of impact, and thus fills a critical gap necessary for rational, evidence-based health
policy discussion in the Commonwealth.
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BACKGROUND
Papillomaviruses are a ubiquitous family of non-enveloped DNA viruses infecting
virtually all amniotes, including humans.14 More than 150 human papillomavirus (HPV) types
have been sequenced and are divided into five evolutionary groups15 found to infect epithelial
mucosa, cutaneous membranes, or both. Clinically relevant HPV types are categorized by their
known associations with human cancers, as either high-risk or low-risk serotypes.
HPV is the most common sexually transmitted infection in the world, with an estimated 6
million or more new infections annually in the United States alone.8 We now know that HPV is
the necessary cause of cervical16 and other cancers,17 being found in 99.7% of all cervical cancer
tissue specimens, low- and high-grade squamous intraepithelial lesions, and abnormal
Papanicolaou (Pap) test results.18 Yet, as recently as 1970, the HPV virus was assumed to be a
monotypic, medically irrelevant, spontaneously cleared nuisance.19 Only during the decades
following the advent and development of recombinant DNA technology20 did a fuller picture
emerge of the diversity of its biology and disease-causing capacity.4,21
HPV exposure most commonly, but not necessarily, results from sexual contact. Though
most infections resolve over time, persistent infections with oncogenic types have been shown to
cause cervical cancer17 – the second most common cancer among women worldwide – and plays
a central role in subsets of several other invasive cancers, including those of the vagina, vulva,22
penis,23 anus,24 oral cavity and pharynx.25 Other diseases associated with HPV types include
precancerous lesions of the cervix (cervical intraepithelial neoplasias),26 oral papillomas, genital
warts, respiratory papillomatosis, and in rare cases, epidermodysplasia verruciformis among the
immunocompromised.27
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Estimates of global deaths attributable to cervical cancer alone28 approximate estimates
of global all-cause maternal mortality29 – the subject of far more international attention than the
former. As much as 88% of these deaths occur in low-income countries.28 Projection of cervical
cancer mortality through 2030 is bleaker, with half a million annual deaths expected.
Furthermore, rates in sub-Saharan Africa are expected to double,30 even though the vast majority
could be prevented by existing vaccine technology. Overall, the direct annual medical costs
attributable to HPV in the USA during the period of 2004-07 was estimated to have been
between 4 and 14 billion USD.31

HPV Vaccine Policy
During the first decade of the HPV vaccine era, national programs have been successfully
implemented, either preemptive or subsequent to WHO recommendations, in countries such as
Australia,32 Belgium,33 Canada,34 Denmark,35,36 France,37 Greece,38 Iceland,39 Israel,40 Italy,41
Japan,42 New Zealand,43 Norway,44 Portugal,45 Singapore,46 Spain,47 Sweden,48 and the United
Kingdom of Great Britain and Northern Ireland.49 Further, many middle- and low-income,
recently developed or developing countries such as Argentina,50 Brazil,51–53 Brunei,54 Mexico,55
Slovenia and Macedonia,56 and Uganda57, among others, have begun national vaccination
campaigns. As of 2016, a total of 86 countries had added the HPV vaccine to their national
vaccination schedules.58 However, international vaccine pricing practices favor high-income
countries, for whom the sum health and economic benefits from the vaccine are greatest,59 which
furthers the irony of low policy and programmatic adoption in the USA.
There is no national vaccination program in the USA. The federal government is highly
limited in its role within vaccine policy and delivery to one of setting agendas, guidelines, and
recommendations. Instead, each state regulates vaccination within its borders largely through
9

laws that require students to prove adherence to a medically-informed, but politically-derived,
vaccination schedule before allowed entry to schools, and in some cases, daycares and colleges.
The Advisory Committee on Immunization Practices (ACIP),60 which informs the official
policies of both the CDC and the Department of Health and Human Services (HHS),
recommends both males and females ages 11 or 12 receive the HPV vaccine. It further
recommends that unvaccinated females between 13-26 and males 13-21 years of age also receive
the full series.61 Many other federal and state health or disease agencies have added HPV
vaccination for both girls and boys before sexual debut to their priority agendas, including the
President’s Cancer Panel,62 the National Foundation for Infectious Diseases,63 and the National
Cancer Institute.64 National medical non-governmental organizations (NGOs) and advocacy
groups, too, have published supportive positions on universal HPV vaccination, including the
American College of Obstetricians and Gynecologists (ACOG),65 the American Academy of
Family Physicians (AAFP),66 the American Academy of Pediatrics (AAP),67 and the American
College of Physicians (ACP).68
For years, HPV vaccine uptake in the USA had remained one of the lowest among the
Organization for Economic Co-operation and Development (OECD) nations, due, in part, to the
fractured and inconsistent nature of healthcare policy and delivery in the US system. But
recently, the USA has made progress in relation to its peers: In 2015, 52.2% (+/- 1.8) of girls and
39% (+/- 1.7) of boys between ages 13-17 had received at least 2 HPV vaccine doses, though
rates varied significantly by region, and state,69 placing the USA more squarely near the mean
for high-income countries (48.5% [CI: 38.6 - 59.3]).70

HPV in Kentucky
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In arguing for a transformative framework for global health justice, and in reference to
impoverished and developing nations, Gostin argued that health inequalities represent an
enduring and consequential global health challenge.71 Yet one need not travel beyond US borders
to identify dramatic examples of “the inequitable distribution of disease and early death”.71
The Appalachian cultural region, which includes parts of 13 eastern USA states and
approximately 25 million people, is characterized by poor socioeconomic, health, and
environmental indicators,72 especially in the central Appalachian states of West Virginia, Ohio,
and Kentucky.73 Appalachian Kentucky, in a state recognized for its high HPV-related cancer
burden74 and low HPV vaccination rates,75 has among the highest HPV-related cancer death rates
– for both males and females – in the United States.76 In addition to the social determinants that
shape health status in Appalachian Kentucky, specific risk factors for the development of HPVrelated cancers are common is this population. High smoking rates, risky sexual behavior,77
lower screening and vaccination rates, high comorbidities,78 and even fatalistic beliefs79 may all
be contributing factors.
The HPV-related cancer incidence rate in non-Appalachian Kentucky has been assessed
at 22.0 and 21.3 per hundred thousand for females and males, respectively. The rate for
Appalachian Kentucky is even higher, at 24.6 and 21.9, female and male.76 Another study
calculated the relative risk of Appalachian Kentuckians for cervical cancer as 1.23 that of nonAppalachian Kentuckians.80 For some counties of Appalachia, like Harlan County, KY, the rate
is nearly three times (21.1) the national rate per hundred thousand (8.1; all values age-adjusted to
the 2000 US Standard Million Population).76 Mortality rates from HPV-related cancers in
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Kentucky are similarly high: 3.2 for cervical cancer (but 4.8 for African American Kentuckians),
0.8 for vaginal and vulvar cancers, and 3.0 for oral and pharyngeal cancers (per hundred
thousand; age-adjusted).81 Therefore, any study of Kentucky health policy must consider the
disparate distribution of disease burden within the state, and therefore the inevitably disparate
distribution of health policy effects.
Until now, Kentucky-specific HPV infection prevalence data has not been available.
However, data collected between 2013 and 2014 by Crosby and Vanderpool, et al.82 has recently
been analyzed for type-specific prevalence and risk factors among a co-screening aged cohort of
398 women in Appalachian Kentucky.13 Any-type HPV prevalence was found to be 55.6%;
33.3% for high-risk, and 45.5% for low-risk types. Fifty percent of those infected were infected
with at least one nonavalent (9vHPV; Gardasil 9™) vaccine type, and 70.5% of infected women
had multiple simultaneous infections. For women in the youngest age group in the study, aged
30-34, the any-type prevalence was 58.3%. This is an important point, because in most studies of
HPV epidemiology to date, the highest prevalence rates have been found among women under
30 years of age, and usually under 25. If similar ratios hold in Kentucky, then the risk pool into
which young Appalachian Kentuckians are sexually debuting may carry a significantly higher
viral load than reflected by these already high prevalence rates, and much higher than the agematched national averages.

HPV Vaccination in Kentucky
Nationally, approximately 40% of girls aged 13-17 had received the (then) full 3-dose
HPV vaccine series in 2014.83 The rate among boys was much lower – nearly half, at 21.6% - but
still an increase of more than 8% over the previous year.83,84 Though the burden of HPV
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infection and disease is higher in Kentucky than in most of the US, HPV vaccine uptake has
lagged, especially among males. According to 2014 data collected and published by the CDC,
the adolescent HPV vaccine completion rate in Kentucky was 37.5 and 13.3% for females and
males, respectively.83 Promisingly, since 2016, CDC guidelines now recommend a 2-dose
schedule for girls and boys under 14 years of age, which is likely to improve compliance rates
going forward, though the degree of its effect is not yet known.85

HPV Vaccine Policy in Kentucky
HPV vaccine legislation has been debated in Kentucky since the 2006 legislative session,
when bills 143, 345, and 327 were introduced in the House. Since then, at least six other bills
have been proposed. During the 2013 regular session, house bill 358 (13RS-HB358), which
proposed to amend KRS 214.034 to require the HPV vaccine for females (ages 9-16) and males
(ages 10-16) entering 6th grade, and to require parental withholding of consent be kept on file by
schools, died in the Kentucky Senate following house passage, 54-40.86 13RS-HB358 is the
closest to evidence-based HPV legislation Kentucky has come, and has therefore been used to
define this study’s simulation parameters for HPV legislation in Kentucky.
The questions addressed by this study, of whether and to what degree Kentucky’s current
vaccination rates may contribute to a herd immunity; or may reduce the overall prevalence of
HPV infection in the Commonwealth; or may impact the health outcomes of current cohorts
compared to those preceding and unvaccinated; or may compare to future cohorts with even
greater vaccine coverage – should legislation like 13RS-HB358, which proposed to add the HPV
vaccine to the state’s school entry schedule of required vaccines, pass in Kentucky – are both
timely and consequential.
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METHODS
Study Goal, Objectives, Aims
Our goal was to generate novel, population-specific quantitative data and to analyze its
practical implications for vaccine policy in the Commonwealth of Kentucky, USA.
The main objectives of this study were twofold. First, to broadly assess the HPV vaccine
landscape, an overview of the virus’ biology, pathology, and epidemiology has been included, as
well as a brief account of the efforts so far put forth to develop, test, distribute, and legislate the
HPV vaccine (see Background section, above).
Second, to address the central question of the impact of HPV vaccine legislation (such as
13RS-HB358) in Kentucky, we have developed a quantitative computer model of HPV infection,
transmission, clearance, and sequelae capable of simulating multiple vaccine policy scenarios.
To facilitate evidence-based health policy decision-making relating to the HPV vaccine, we
focused on the outcomes of three relevant scenarios:
1. No vaccination: a vaccination rate of zero was used as a control for comparison of scenarios
2 and 3 to a pre-vaccine baseline. In this way, both the progress so far, as well as the health
and economic impacts of vaccine legislation, could be estimated.
2. Current vaccination: the current HPV vaccination rates83 were used to simulate Kentucky’s
current trajectory and expected benefits should rates remain at current levels.
3. Required vaccination: the HPV vaccination rate was matched to the average compliance rates
for Kentucky’s currently scheduled 6th-grade entry vaccines (the TDAP booster and the
meningococcal vaccine; 2014-16) to simulate passage of legislation similar to 13RS-HB358.
The simulation model herein described was adapted from a previously developed and
published model87 originally tailored to Danish36 and Irish populations.88 Parameters of the model
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were calibrated to reflect Kentucky’s unique incidence, prevalence, risk factors, and population
characteristics. Using an agent-based transmission approach, the model simulates infection and
disease dynamics over time. At simulation endpoint, model agent states were interpreted as
population outcomes, translated to measures of health impact, or extrapolated to address
questions of economic impact.
Using this policy impact model for 13RS-HB358, several specific aims were addressed.
The primary aim was to determine and compare the epidemiological patterns of infection (in
terms of type-specific prevalences) and health outcomes (in terms of cancers prevented and lives
saved, measured from baseline) of scenarios 2 and 3.
Next, we calculated the health impact of 13RS-HB358 in terms of the differences in life
years and quality-adjusted life years (QALYs) gained over baseline between the two vaccine
scenarios.
Finally, to assess the long-term direct economic impact of 13RS-HB358, we calculated the
society-payer perspective costs associated with vaccination against future healthcare
expenditures averted as an incremental cost-effectiveness ratio (ICER), or cost per QALY, using
the oft-cited benchmark of 50,000 USD as the comparative measure of utility.

The Model: Policy Simulations
With the recent arrival of cervical cancer vaccines, modeling studies have become
increasingly common and complex, with researchers and agencies alike eager to inform historic
policy developments in countries all over the world. The models used vary in step with the
complexity of the variables involved, creating a large number of distinguishing characteristics
and a variety of model strengths to consider.
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To determine which model type would be best suited to this study’s goals and objectives,
many different characteristics were evaluated: time horizons and discounting;
comprehensiveness of included diseases and their natural histories; effectiveness and duration of
vaccine-induced protections; herd and cross immunities (i.e., protections to those not directly
vaccinated, and protections to HPV types not specifically included in the vaccine, respectively);
quality of life; costs and payer perspectives; uncertainty;89 and the flexibility to accommodate the
sex behaviors, age distribution, relevant risk factors, type-specific prevalences, and disease
progression rates unique to the population of interest.90

Model Type and Targets
In the end, a stochastic, susceptible-infectious-susceptible (SIS), agent-based dynamic
model, originally developed by Jens Olsen with the Centre for Applied Health Services Research
and Technology Assessment (CAST), University of Southern Denmark, was selected.
Commissioned by the Danish government to inform its national HPV vaccine policy, the model
simulated the transmission biology of HPV types 6, 11, 16, and 18 under the condition of several
assumptions, including 100% vaccine effectiveness and lifetime duration of immunity. Herd
immunity is accounted for by the dynamic modelling environment, but it does not recognize
cross-immunity to other HPV types. The stochastic agent-based model allows for fine calibration
of the sex behaviors, age-specific prevalences, and disease progression rates to the study
population. The model uses the NETLOGO multi-agent modeling environment (version 5.3.1;
http://ccl.northwestern.edu/netlogo/). For this study, the model was significantly expanded to
include all viral types covered by the 9-valent HPV vaccine, and adapted to Kentucky’s unique
population to address the following scenarios (Table 1):
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1. No Vaccination: the cumulative outcomes given no vaccination as a baseline measure against
which to compare each of the experimental scenarios
2. Current Vaccination: the cumulative outcomes given 9vHPV vaccination rates of 37.5 and
13.3 percent among 11-year-old girls and boys, respectively
3. Required Vaccination: the cumulative outcomes given 9vHPV vaccination of 83.125
percent91 of 11-year-old boys and girls

Table 1. Vaccination coverage of 11-year-olds for HPV-MOK simulation scenarios.
Scenario
1. No vaccination (pre-vaccine era)
2. Current vaccination (present day)

83

3. Required vaccination (13RS-HB358)

91

Vaccination coverage, girls

Vaccination coverage, boys

0%

0%

37.5%

13.3%

83.125%

83.125%

Disease Model Characteristics
The new model, forthwith referred to as the HPV Model of Kentucky (HPV-MOK),
simulates the infection dynamics of the high-risk types 16, 18, 31, 33, 45, 52, and 58, as covered
by the nonavalent (9vHPV) vaccine, Gardasil 9. These types have been shown to account for
most cervical, vulvar and vaginal, anal, oropharyngeal, and penile precancers and cancers,
including 90% of all cervical cancers.61 In addition, the model simulates low-risk types 6 and 11,
also covered by the 9vHPV vaccine, which are believed to cause at least 90% of all anogenital
warts,92 and at least 90% of juvenile onset recurrent respiratory papillomatosis (JORRP).93 HPVMOK was also programmed to simulate Kentucky’s unique epidemiology of HPV-related
cervical diseases (Table 2).
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Table 2. HPV-MOK pre-simulation calibration parameters, targets, and values.
Parameter

Prevalence Target*, %

Value achieved, %

HPV6

2.66

2.30

HPV11

0.16

1.12

HPV16

5.03

5.13

HPV18

1.87

2.08

HVP31

2.38

2.52

HPV33

1.13

1.55

HPV45

1.87

2.03

HPV52

3.33

3.27

HPV58

1.59

1.62

Parameter

Incidence Target, %

Value achieved, %

94

CIN1

0.29

81

Cervical Cancer, incidence

0.015

Parameter

Value

0.32
0.014

Source

Cervical cancer screening rate 81.3; Present KY screening rate

CDC BRFSS95

Age at death

76.26; Present KY life expectancy

US Census data

Initial age distribution

Present Kentucky age distribution

US Census data

Initial gender distribution

Present Kentucky gender distribution US Census data

*Estimated KY prevalences from national (NHANES96) and regional (Appalachian Kentucky13) data, adjusted by geographic population
distribution and age.

Model Assumptions and Variables
With any model, the advantages of simplifications are weighed against their effects on
the validity and reliability of predictions. In this case, several simplifications of transmission and
clearance dynamics were assumed:
•

Heterosexual population

•

HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 only

•

Persistent HPV infections with an exponential distribution of duration

•

No natural immunity

•

No cross protection
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•

No vaccine failure and no waning efficacy

•

No risk factors beyond sexual behavior
Because non-cervical HPV infection and disease course progression are poorly

understood, it is difficult to realistically model the underlying biological processes of these
conditions. To simplify the model while maintaining coherence with real-world measures, the
incidences of HPV-related non-cervical disease were assumed to decrease proportionately with
that of cervical cancer, which HPV-MOK models directly and in detail. Population variables
include viral transmission and clearance dynamics, disease progression and regression
probabilities, and similar universally-applicable probabilities. Other variables are agent-specific,
distinguishing this class of dynamic modeling from static procedures (see Table 3 for a full list of
simulation variables).
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Table 3. HPV-MOK simulation variables.
Variable

Value

Source

HPV → CIN1

0.009; Probability per month

Elbasha et al.97

CIN1 → HPV/clear (regress) 0.329; Probability per year
CIN1 → CIN2

0.136; Probability per year

CIN2 → CIN1 (regress)

0.133; Probability per year

Values determined from model
calibration

CIN2 → CIN3

0.10; Probability per year

CIN3 → CIN2 (regress)

0.03; Probability per year

CIN3 → LCC → RCC → DCC

0.10 per progression; Probability per year

HPV 6/11 → genital warts

0.075; Probability per year

Risk of HPV 6/11/16
infection

0.35; probability per intercourse

Elbasha et al.97

Risk of HPV 18, 31, 33, 45,
52, or 58 infection

Proportional to HPV 16 based on measured
prevalence ratios

Modified compared to the HPV 16
risk to reflect their lower
prevalences

Concurrent partners

0, 1, or 2, uniform/block distribution

Estimate

Duration of relationship (in
months)

Dependent on age: the older, the longer
duration (Y = abs random-normal (0.8·age –
12) (age/0.5)·12).

Estimate

Frequency of sexual
intercourse

Random-gamma distribution with a mean of
9.48 per month; SD 9.95

Burchell et al.98

Vaccination status

0 or 1

Duration of infections:
HPV 6
HPV 11
HPV 16
HPV 18
HPV 31
HPV 33
HPV 45
HPV 52
HPV 58

Exponential distribution means:
11.32
9.50
14.6
11.26
11.518
11.3
11.51
12.40
11.14

Duration of genital warts

Random-gamma 6 1.5

Values independently defined
during model calibration

Following the “expert consensus” described by Ultsch et al. for dynamic model
simulations,89 the simulations were allowed to run until epidemiological equilibrium was
achieved to assure that all positive and negative effects of the experimental variable (vaccination
rate) would be captured across policy scenarios. The model was repeatedly run for 250 simulated
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years, its output analyzed, and the type-specific durations of infection were calibrated until the
model achieved a viral prevalence steady-state consistent with Kentucky’s real-world rates
(Table 2). Type-specific prevalences were calculated from both national and regional published
epidemiological data. NHANES, a nationally representative health dataset with HPV prevalence
measures from the pre-vaccine era was used as proxy for non-Appalachia Kentucky. Though
limited, existing data from Appalachian Kentucky suggests regional HPV prevalences
significantly higher than national averages, so proportionately weighted composite age-adjusted
prevalences drawn from both sources were used to define the HPV-MOK seed population. A
model limitation was identified during calibration involving the low prevalence target for HPV
11. The virus type could not be stabilized at such a low rate in the relatively small simulated
populations. However, by adjusting the probability of condyloma formation, the condyloma
prevalence rate target was still matched.
Next, the model was again repeatedly run for 250 years in order to calibrate the pathology
progression and regression variables to reproduce known Kentucky cervical cancer incidence at
steady-state rates (Table 3).

Model Outputs
Once calibrated, the scenarios were run in 4 replicates, each with an initial population of
25,000 nodes. A post-analysis time horizon of 66 years was adopted to accommodate the full
lifespan of the first vaccinated cohorts. Model outputs for each scenario were collected, replicate
data were combined, and all data were transformed and analyzed using Google Sheets (Google
Inc, 2017, Mountain View, CA), a web-based spreadsheet software.
The 9vHPV type-specific prevalences were calculated and are reported as population
proportions for each scenario. The HPV-related disease incidences and mortality rates across
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scenarios were assessed, adjusted (Table 4), and are reported for scenarios 2 and 3 as cancers
prevented and lives saved per hundred thousand persons without discounting.

Table 4. HPV-MOK post-simulation pathology parameter adjustment targets.
Pathology

9vHPV proportion Incidence*,81

Mortality*,81 Mean age at diagnosis

Cervical Cancer

0.9099

16.7

3.2

49100

Vulvar Cancer

0.63101

10.1

0.6

68102

Vaginal Cancer

0.73101

1.9

0.3

60103

Anal Cancer

0.95104

2.4

0.2

61105

Oropharyngeal Cancers

0.66101

13.3

3.0

53106

Penile Cancer

0.57101

2.0

0.2

68107

Condyloma

1.0108

194.5109

JORRP

1.0110

4.3111 (per 100k <14yo)

N/A

*Annual rate, per 100 thousand population

The QALYs gained in scenarios 2 and 3 were calculated by comparing the reduction in
morbidity and mortality in each from those in the baseline control scenario (see Table 5 for
QALY weights by age and disease burden). Life-years gained were determined from differences
in the age distributions for cancer deaths versus the general population, multiplied by the annual
HPV-related cancer mortality rates in each scenario. Future life-years and QALYs were
discounted at the same rate as future monetary costs and savings.

22

Table 5. HPV-MOK life-year quality adjustments and unit costs per variable.
Variable
Age Group
00-08
09-14
15-19
20-24
25-29
30-34
35-39
40-44
45-49
50-54
55-59
60-64
65-69
70-74
75-79

QALY Modifier87,112 Unit Cost*; PV, USD
N/A
1.0
1.0
0.92880
0.92880
0.92880
0.92365
0.90475
0.89405
0.89005
0.86560
0.87060
0.86495
0.84495
0.83785
0.81330

CIN1

0.91

2,412.84113

CIN2

0.87

6,215.17114,115

CIN3

0.87

7,056.49114,115

Locally invasive Cervical Cancer (LCC)

0.76

45,291.20114,115

Regionally invasive Cervical Cancer (RCC)

0.67

48,516.54114,115

Distant metastasis Cervical Cancer (DCC)

0.48

77,715.20114,115

Vulvar Cancer

0.68

30,802.80116

Vaginal Cancer

0.68

35,342.15116

Anal Cancer

0.68

53,414.27116

Oropharyngeal Cancers

0.68

77,769.26106

Penile Cancer

0.68

25,802.67116

Condyloma

0.91

991.84116

JORRP

0.69

143,411.45116

0.001117
0.076118

476.74
204.8760
33.00119
65.42120,121
4,768.18120,121

Vaccination
Vaccine (x2)
Administration (x2)
Mild reaction (probability: 0.00105)
Severe reaction (probability 0.00009)
Screening
Office visit
Cytology
HPV DNA test
Patient time

165.94122
30.96
37.15
68.11
29.72

*Medical costs of treatment, estimated cost of vaccination, or estimated cost of cervical cancer screening per incident.
PV: Present value. USD: United States dollars.
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Following Gold et al.’s recommendations,123 HPV-MOK uses a societal perspective that
includes costs – vaccination costs, cancer screening costs, and future healthcare sector costs of
treatment for HPV-associated diseases – and benefits, regardless of payer or beneficiary. The
direct policy costs were limited to the financial cost of the 2 dose HPV vaccine series, set at
204.87 USD per dose per person,124 plus 33.00 USD for each vaccine administration,119 and any
medical costs associated with rare vaccine reactions (Table 5).120 These are reported in USD
after adjustment for inflation and discounting.
The nature of prevention regularly puts the costs of intervention near the present, with
subsequent benefits delayed into the far future. This distinctive characteristic of prevention
renders decisions based on evaluations of relative value, whether by legislators considering
policy or an individual considering personal choices, vulnerable to the irrational biases inherent
to human psychology. The HPV-MOK uses a 3.0% discount rate for all future costs (whether
incurred or averted) and benefits to account for the time value of money, but does not further
discount for time preference.125
Future averted costs of treatments for genital warts, JORRP, CIN1-3 and atypia, cervical
cancer, genital cancers, and head & neck cancers were estimated from the available literature to
reflect present value (Table 5) and are described in USDs. Results from simulations were
discounted and adjusted for inflation. Because the cost of healthcare is expected to continue to
outpace the general economic inflation rate for the foreseeable future, both a healthcare inflation
factor and a consumer price index inflation factor were incorporated in our estimates (Table 6).
A broader projection of total economic costs relating to the modeled policy, including the
opportunity, legislative, and implementation costs (recurrent and operational) was not included
in this analysis.
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Table 6. Economic and population terms.
Variable

Value, %

Reference

Personal Consumption Expenditure (PCE)
price index average inflation (2006-15)

1.62

Bureau of Economic Analysis, US Department of
Commerce National Accounts (NIPA) data archive126

CMS NHEA healthcare inflation rate,
averaged projections (2017-26)

5.49

Centers for Medicare & Medicaid Services, Office of the
Actuary National Health Expenditure Account127

Discount rate for both costs and effects

3.0

Second Panel on Cost-Effectiveness in Health and
Medicine128

Annual population growth, Kentucky

0.42

Kentucky State Data Center Projections of Population
and Households129

The World Health Organization (WHO) recommends that cost-effectiveness be
considered in HPV vaccine policy decisions.130 We therefore incorporated the adjusted monetary
values for costs and benefits into calculations of incremental cost (defined as direct policy costs
minus future costs averted, in USD) per QALY gained (without equity weightings)131 to assess
the potential cost-effectiveness of legislation similar to 13RS-HB358 in Kentucky.
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RESULTS
Aim 1: Patterns of Infection and Health Outcomes
HPV type-specific prevalences varied across scenarios (Figure 1). While prevalences
were fairly stable through time in Scenario 1 (steady-state), both vaccination scenarios resulted
in a steep decline in all HPV types soon after vaccine introduction (at time point zero). In
Scenario 2, several of the modelled types were eventually eliminated from the population despite
relatively low vaccination coverage, suggesting a strong herd effect. Also in Scenario 2, types 16
and 52 achieved a new steady-state prevalence in the population approximately 25 years after
vaccine introduction (Figure 1-b). In contrast, Scenario 3 saw all 9 types eliminated from the
population within about 13 years of vaccine introduction (Figure 1-c).
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Figure 1. 9vHPV type-specific prevalences among scenarios 1 – no vaccination (a), 2 – current
vaccination rates (b), and 3 – required vaccination under proposed policy (c).
a

b

c

The cervical disease burden associated with the 9 HPV types studied was, in the prevaccine world modelled by Scenario 1, stable and comparable to real-world historical incidence
rates observed for Kentucky (Figure 2-a and Table 2). Upon vaccine introduction in both
Scenarios 2 and 3, 9vHPV-related cervical disease incidences dropped precipitously, with
condylomas eventually being eradicated from the simulated populations. Scenario 2 saw an
average drop in CIN1 incidence by nearly three-quarters and achieved low steady-state rates of
all cervical precancerous pathologies within 25 years (Figure 2-b). Meanwhile, new
precancerous lesions were eliminated completely in Scenario 3 within just 15 years (Figure 2-c).
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Cervical cancer, attributable to older uncleared infections, followed a slower decline in both
scenarios, and was eventually eliminated from scenario 3 once the pre-vaccine era population
had expired (the last cancer case occurred in year 64 after vaccine introduction; Figure 2-c).

Figure 2. 9vHPV-related cervical disease among scenarios 1 – no vaccination (a), 2 – current
vaccination rates (b), and 3 – required vaccination under proposed policy (c).
a

b

c
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Non-cervical cancers were not directly modelled but were assumed to track
proportionally with cervical cancer. Additionally, incidences of JORRP were assumed to decline
proportionally with the declining prevalences of HPV types 6 and 11 in the vaccination
scenarios. Figure 3 shows the relative annual incidences of non-cervical 9vHPV-related cancers
calculated from simulation outputs. In both vaccination scenarios, incidences of non-cervical
cancers fell, and were virtually eliminated over the full time horizon of Scenario 3 (Figure 3-c).

Figure 3. 9vHPV-related non-cervical cancer incidence rates among scenarios 1 – no vaccination
(a), 2 – current vaccination rates (b), and 3 – required vaccination under proposed policy (c).

a

b

c
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Table 7 shows the annual incidence averages of 9vHPV-related diseases per hundred
thousand population. Again, only cervical diseases, including condylomas, were directly
simulated by the HPV-MOK model; other pathologies were extrapolated proportionately from
model outputs. Nevertheless, the results are consistent, showing a dose-effect decline in all
9vHPV-related pathologies with increasing vaccine coverage in the population.

Table 7. Average annual incidences per hundred thousand population for 9vHPV-related
diseases across three HPV-MOK simulation scenarios of Kentucky’s next 66 years.
Diseases
Cervical Pre-cancers
CIN1
CIN2
CIN3
Cancers
Cervical
Oropharyngeal
Anogenital
Vaginal
Vulvar
Penile
Condylomas
JORRP

S1: incidence rates S2: incidence rates S3: incidence rates
290.00
122.98
23.55

82.82
37.04
7.45

27.86
14.39
3.22

15.03
8.78
2.28
1.39
6.36
1.14

10.94
6.39
1.66
1.01
4.63
0.83

8.76
5.12
1.33
0.81
3.71
0.66

194.50

25.93

12.83

0.88

0.16

0.08

Deaths attributable to the 9vHPV types, which were calculated as a proportion of cervical
cancer mortality rates, declined over time following introduction of the 9-valent vaccine in
scenarios 2 and 3 (Figure 4 and Table 8). The required vaccination policy in Scenario 3 nearly
eliminated 9vHPV-related deaths within the lifetime of the first policy cohort (Figure 4-c).
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Figure 4. 9vHPV-related mortality among scenarios 1 – no vaccination (a), 2 – current vaccination
rates (b), and 3 – required vaccination under proposed policy (c).
a

b

c

Table 8. Annual averages per hundred thousand population for 9vHPV-related mortality across
three HPV-MOK simulation scenarios of Kentucky’s next 66 years.
Diseases
Cancers
Cervical
Oropharyngeal
Anogenital
Vaginal
Vulvar
Penile

S1: mortality rates S2: mortality rates S3: mortality rates
2.88
1.98
0.19
0.22
0.38
0.11

2.10
1.44
0.14
0.16
0.28
0.08

1.68
1.15
0.11
0.13
0.22
0.07
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Aim 2: Health Impact
From disease-specific mortality rates, life-years and QALYs lost were calculated. When
compared to the pre-vaccine conditions of Scenario 1, both vaccine scenarios showed an inverse
linear relationship between vaccine coverage and cancer deaths (Figure 4), and a positive linear
relationship of coverage with both life years (Figure 5) and QALYs gained (Figure 6). As
expected, Scenario 3’s higher vaccination rate produced the greater slope, though the model’s
dramatic herd effect reduced the proportional rate of return for vaccination overall. On average
annually, Scenario 1 lost 55.4 life years per 100 thousand population to 9vHPV-related cancers;
Scenario 2 lost 47.5, and Scenario 3 lost 42.4 life years per 100 thousand. A more dramatic ratio
was observed for QALYs lost, with Scenario 1 losing an average of 87.4 QALYs per 100
thousand population to 9vHPV-related diseases annually, compared to 61.8 and 51.4 in
Scenarios 2 and 3, respectively.

Figure 5. Annual life-years gained per 100k population over 66 years in two 9vHPV vaccination
scenarios vs. no vaccination.
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Figure 6. Annual QALYs gained per 100k population over 66 years in two 9vHPV vaccination
scenarios vs. no vaccination.

Aim 3: Economic Impact
Figure 7 shows the total annual economic costs per hundred thousand population for
prevention, screening, and treatment of diseases associated with 9 types of HPV, at current value
after discounting and adjusting for general inflation. Scenario 1 predicted an annual screening
and treatment cost range of 5.1m to 12.4m (8.4m average) USD per hundred thousand over the
next 66 years, vs. the 4.5m to 7.5m (5.8m average) predicted by Scenario 2, and the 4.4m to
7.2m (5.4m average) predicted by Scenario 3 (Table 9), which both include the additional costs
associated with the HPV vaccine. Total costs remained close during the first 20 years of
simulations, with a dramatic annual savings attributable to vaccination emerging and growing
after that.

33

Figure 7. Total discounted costs per 100k population for prevention, screening, and treatment of
9vHPV-related diseases over 66 years among scenarios 1 – no vaccination, 2 – current
vaccination rates, and 3 – required vaccination under proposed policy.

Table 9. HPV-MOK breakdown of annual averages per hundred thousand population for 9vHPVrelated costs across three scenarios of Kentucky’s next 66 years.
Expenditures S1: costs (PV; USD) S2: costs (PV; USD) S3: costs (PV; USD)
N/A

212,892

696,718

Screening

3,123,826

3,123,826

3,123,826

Treatment

5,279,080

2,463,323

1,611,607

8,402,906

5,800,041

5,432,151

Vaccination

Totals:

PV: present value. USD: United States dollars.
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DISCUSSION
Using a stochastic, susceptible-infectious-susceptible (SIS), agent-based dynamic model,
the long-term health and economic impacts of legislation adding the 9vHPV vaccination to the
6th grade school entry schedule for both boys and girls in the state of Kentucky was estimated.
The model simulated the transmission dynamics of 9 HPV types, and the pathological
progression of related cervical disease. Model outputs were aggregated, extended to account for
other HPV-related pathologies, and analyzed to determine such legislation’s health effects and
cost-effectiveness.

Major Findings
Given base assumptions of stable screening rates, stable healthcare and general economic
inflation, stable population growth, exclusive use of the 9vHPV vaccine and stable vaccine costs,
100% vaccine efficacy, and a discount rate of 3.0% applied to economic and health impact
measures, Scenario 1, which represented the state of Kentucky from the pre-vaccine era,
predicted a total of approximately 118 thousand 9vHPV-related cancers and 19.5 thousand
subsequent deaths, together costing 180 thousand life-years, 283 thousand quality-adjusted lifeyears, and 28.6 billion USD in direct healthcare utilization in the state of Kentucky over 66
years.
Scenario 2, based on current vaccination coverage in the state, predicted fewer total
cancers (83.6 thousand), cancer deaths (13.8 thousand), life-years lost (151 thousand), QALYs
lost (195 thousand), and reduced direct costs (19.4 billion USD) over the next 66 years, giving us
a picture of what might be expected from the real-world status quo.
Scenario 3, representing Kentucky after passage of legislation similar to 13RS-HB358,
and using an estimated vaccine uptake rate of 83.125%, predicted still fewer 9vHPV-related
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cancers, deaths, life-years and QALYs lost, and lower direct costs than Scenarios 1 and 2 (Table
10).

Table 10. HPV-MOK cumulative HPV-related disease outcomes and costs across three
vaccination scenarios of Kentucky’s next 66 years under base assumptions.
S1: No Vaccination S2: Current Vaccination S3: Required Vaccination
Cancers

118,104

83,560

65,607

Deaths

19,452

13,763

10,806

Life-years lost (PV)

179,699

151,251

133,299

QALYs lost (PV)

282,675

195,378

160,706

Costs (PV; USD)

28.615b

19.439b

18.144b

PV: present value. USD: United States dollars.

HPV-MOK predicted that uptake of the 9vHPV vaccine at current levels (as in Scenario
2) will, over 66 years, prevent 34.5 thousand cancers, save nearly 6 thousand lives, preserve 28
thousand life years and 87 thousand QALYs, and save 9.176 billion USD in healthcare
expenditures that would have occurred in Kentucky over 66 years had the vaccine not been
developed or adopted. This large effect is out of proportion to the scale of direct vaccine
coverage in Scenario 2, indicating a large herd effect predicted by the model’s transmission
algorithms that may not reflect real-world dynamics and outcomes.
When simulating higher vaccination rates consistent with what could be expected from
passage of legislation requiring the 9vHPV vaccine for school entry in Kentucky, HPV-MOK
predicts the prevention of a total of 52.5 thousand cancers and nearly 9 thousand deaths, saving
46 thousand life-years, 122 thousand QALYs, and 10.470 billion USD that would have been lost
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without the vaccine (Table 11). But neither of these comparisons tells us what effect a policy like
13RS-HB358 could have in the real post-vaccine world of Kentucky in 2018.
Looking forward over 66 years along 2 diverging paths, one representing policy inaction
and stagnant vaccine uptake growth, the other legislative action adding the 9vHPV vaccine to the
school entry schedule for all 6th graders in the state, the latter could see Kentucky prevent 18
thousand cancers and 3 thousand deaths, saving nearly 18 thousand life years, 35 thousand
QALYs, and 1.294 billion USD, for an estimated ICER per QALY of negative 37 thousand USD
over the former path of policy inaction (Table 11). From this, we conclude that a bill like 13RSHB35 would not only be cost-effective in Kentucky, but could be cost-saving. This is likely
attributable to 1) Kentucky’s high HPV prevalence and high HPV-related disease burden, 2) the
state’s currently low rates of HPV vaccination, especially among boys, 3) this study’s
comprehensive inclusion of all direct 9vHPV-related costs and effects, and 4) the savings
realized from fewer required vaccine doses (from 3 to 2 doses per most recent guidelines).

Table 11. Vaccine impact: vaccine era vs. pre-vaccine era under base assumptions.
S1:S2 Current gains over S1:S3 Potential policy gains S2:S3 Policy Impact over
pre-vaccine era
over pre-vaccine era
current vaccination rates
Cancers prevented

34,544

52,497

17,953

5,690

8,647

2,957

Life-years gained (PV)

28,449

46,400

17,952

QALYs gained (PV)

87,296

121,969

34,672

Savings (PV; USD)

9.176b

10.470b

1.294b

-105,114

-85,845

-37,330

Lives saved

ICER (PV; USD)
PV: present value. USD: United States dollars.
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Sensitivity Analysis
The sensitivity of the model’s predictions to discount rate and time horizon was explored,
per expert consensus.89 Table 12 shows that, even though outcome and impact benefits are
heavily weighted to the far future, and even though Scenario 2 produced a much larger herd
immunity effect than expected, which reduced the measured impact of Scenario 3 by
comparison, ICERs per QALY in the policy scenario remained well below the 50,000 USD
threshold for utility even with the most unfavorable tested values for vaccine cost, time horizon,
and discount rate. Thus the conclusion of cost-effectiveness is robust despite the model’s
sensitivity to discounting, discount rate, vaccine pricing and dosing, and time horizon.

Table 12. HPV-MOK policy impact: sensitivity to discounting, discount rate, dosing, and time
horizon, S2:S3.
Impact measures
At time horizons; PV 1.5%*

Discount Rates
1.5%

3.0%

5.0%

10.0%

66-years
QALYs gained
107,025 58,893 34,672† 19,035 6,763
Cost (USD)
-2.6b
-2.6b
-1.3b†
-0.5b -65m
3-dose cost (USD)
-1.1b
-1.1b
-0.5b
-0.1b
67m
ICER (USD)
-24,155 -43,897 -37,330† -28,003 -9,732
3-dose ICER (USD) -10,254 -18,634 -13,667 -6,210 9,915
40-years
QALYs gained
52,259 34,592
Cost (USD)
-0.9b
-0.9b
3-dose cost (USD)
-0.3b
ICER (USD)
-17,411 -26,303
3-dose ICER (USD)
-9,436
20-years
QALYs gained
Cost (USD)
3-dose cost (USD)
ICER (USD)
3-dose ICER (USD)

8,013
-24m
-3,053

7,222
-24m
0.2b
-3,388
26,811

23,695 15,131 6,433
-0.6b
-0.3b -52m
-0.1b
-14m
71m
-23,579 -19,250 -8,126
-5,991
-944 11,062
6,512
-20m
0.2b
-3,165
25,414

5,681 4,065
-15m ~500k
0.1b
97m
-2,585
119
24,176 23,802

PV: present value. USD: United States dollars.
*Discounting applied to monetary values only; Life-years and QALYs not discounted.
†Base case conditions.
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Limitations
This study has a number of limitations common to complex simulations. First, none of
the model’s assumptions hold perfectly with reality. Screening rates, economic terms, natural
immunity, vaccine efficacy and duration of immunity, and many others are simplifications that
affect the model’s fidelity in unmeasured ways. Second, because only heterosexual transmission
was considered, the effects of transmission dynamics and elevated prevalence rates among
homosexuals were left out of simulations. Third, the model assumes a closed society, though
globalization and regional economics drive immigration and emigration patterns in Kentucky
now and likely even more so in the future. Fourth, the model assumes cervical cancer screening
practices will remain constant into the future, though this is unlikely given the effectiveness of
the HPV vaccine, especially if there is widespread state-level legislative action in the near term.
Whatever changes to screening practices may unfold in the future, they are unaccounted for here.
Fifth, multiple sources originally documenting differing populations and dates were necessarily
used to compile QALY weights, treatment cost estimations, disease incidences, and type-specific
prevalences, which can lead to discrepancies and inaccuracies when combined, though all efforts
were made to minimize such instances. Finally, natural variations in 9vHPV type prevalences
and related disease incidences that might occur in the future were not considered by the HPVMOK, which bounds our findings temporally to policy action in the near-term. Should a policy
decision be significantly delayed, the accuracy of the current analysis may wane.

Conclusions
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Based on the results of this study, Kentucky could prevent cancers, save lives, and save
money by vaccinating as many 11-year-old boys and girls with the 9vHPV vaccine as possible.
Given the slow pace of vaccine uptake in the state since 2006, the most effective path toward
universal vaccination is likely through legislative action at the state level. Despite sensitivity to
variable variances, the conclusion of cost-effectiveness is robust. Further, through much of the
variance range, the model predicts overall cost savings from legislation passage. Most
importantly, the model predicts that HPV vaccine legislation could save many lives and prevent
a great deal of suffering for present and future generations in the Commonwealth.
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